All indications for omalizumab (Xolair) that are not expressly listed in this policy are considered experimental and investigational. Examples called out in the policy include allergic bronchopulmonary aspergillosis (ABPA), allergic conditions without asthma, allergic rhinitis, atopic dermatitis/eczema, eosinophilic esophagitis, food allergy, urticarial vasculitis, cutaneous mastocytosis, and use as an adjunct to subcutaneous immunotherapy. Requests for these unlisted indications should be supported by high-quality evidence and may be reviewed on a case-by-case basis; absent adequate evidence, coverage is typically not provided.

Omalizumab is not indicated for relief of acute bronchospasm or status asthmaticus. For the allergic asthma indication, dosing is determined by baseline total serum IgE and body weight; the FDA label specifies a baseline IgE entry range of 30–700 IU/mL (and a maximum body weight of 150 kg) for dose calculation. Re-testing of IgE during active therapy should not be used to alter dose because total serum IgE levels rise after administration of omalizumab.

Use of omalizumab in children younger than 6 years is not supported by the evidence cited in this policy. Pediatric trial data in the 6 to <12 year age group show some reduction in exacerbations, but guideline and HTA assessments have raised concerns about modest efficacy versus safety and cost, and several bodies recommend limiting routine use to older pediatric or adolescent patients.

When requested for indications that lack controlled trial evidence, such uses may be excluded from routine coverage. The policy cites limited or terminated randomized trials and predominance of case series for several indications (for example, ABPA in people with cystic fibrosis), and indicates that absence of high-quality RCT data is a rationale for treating such indications as investigational unless strong clinical justification is provided.

For eosinophilic esophagitis (EoE), available randomized trial evidence did not demonstrate symptomatic or histologic benefit with omalizumab. A prospective, randomized, double‑blind, placebo‑controlled trial reported no reduction in EoE symptoms or esophageal tissue eosinophil counts compared with placebo, and therefore omalizumab is not supported for EoE based on current trial data.

The available evidence for omalizumab in non‑atopic (non‑allergic) asthma is preliminary. Small mechanistic and early clinical studies suggest biological effects (for example, reduction in FcεRI expression) and possible clinical benefit, but data are insufficient to establish routine coverage for non‑atopic asthma. The document lists non‑allergic asthma among indications considered investigational until stronger RCT evidence is available.

Key: NA — not approved and no data available for this age group. (This designation is used in the inhaled corticosteroid dosing table entries where certain pediatric dose categories are marked as NA because the product is not approved or data are lacking for that age group.)

Re‑testing of total serum IgE during the course of omalizumab therapy is not considered medically necessary for dose determination because total serum IgE levels increase after administration and remain elevated for up to one year; the dose should be based on the pre‑treatment IgE measured before the start of therapy (with re‑testing only after interruptions of ≥1 year).

Use of omalizumab for indications lacking FDA approval or compendial support may be denied or considered not medically necessary. The policy lists numerous off‑label indications as experimental/investigational and notes that requests for such uses should be supported by robust evidence; absent such support, coverage for non‑labeled indications is not routinely provided.

For cystic fibrosis patients with allergic bronchopulmonary aspergillosis (ABPA), randomized trial evidence is insufficient. The Cochrane reviews identified only one small, prematurely terminated randomized trial (n≈14) with incomplete data and a higher rate of serious adverse events in the omalizumab arm; consequently, routine coverage for ABPA in CF is not supported without clear clinical justification and case review.

Use of omalizumab for atopic dermatitis/eczema is not established. Although biologic approaches including anti‑IgE therapy have theoretical rationale and small studies exist, large randomized controlled trial evidence demonstrating consistent clinical benefit is lacking; therefore routine use for atopic dermatitis is generally considered not medically necessary outside of clinical trials or well‑documented refractory cases.

The policy reiterates that omalizumab is not supported for eosinophilic esophagitis: a randomized, double‑blind, placebo‑controlled trial in adults showed no improvement in symptoms or tissue eosinophil counts with omalizumab versus placebo, so EoE is not an evidence‑based indication for routine coverage.

Use of omalizumab in patients with baseline total serum IgE substantially above the labeled adult dosing range remains inadequately supported by high‑quality evidence. Registry and retrospective reports include patients with IgE >700 IU/mL and suggest possible benefit, but the data are observational and limited. The policy indicates that treatment in adults with IgE well above 700 IU/mL lacks robust RCT support and may require strong justification for coverage.

Background: Omalizumab (Xolair) is a humanized anti‑IgE monoclonal antibody approved by the U.S. Food and Drug Administration for allergic (IgE‑mediated) asthma in patients aged ≥6 years, for chronic spontaneous urticaria (CSU) in patients aged ≥12 years, and for add‑on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults ≥18 years. The agent is administered subcutaneously and dosing for asthma and CRSwNP is calculated from baseline total serum IgE and patient body weight, whereas CSU dosing is a fixed 150 mg or 300 mg subcutaneous dose every 4 weeks per clinical guidance and trials.